Table 2.
Patient survival correlates with the presence of TIL in various tumor types.
| Nb of patients a | T cell infiltration | 5-year survival (%) | ||
|---|---|---|---|---|
| Colon adenocarcinoma | 276 | absent | 30 | * |
| Ropponen, 1997 [59] | weak | 45 | ||
| mild | 70 | |||
| dense | 75 | |||
| Colon adenocarcinoma | 371 | CD8+ low b | 50 | * |
| Chiba, 2004 [52] | CD8+ high | 80 | ||
| Colon adenocarcinoma | 959 | CD45RO+ <250/mm2 | 24 | |
| Pagès, 2005 [53] | CD45RO+ >250/mm2 | 46 | ||
| Colon adenocarcinoma | 286 | CD3+ low b | 85 | * c |
| Laghi, 2009 [56] | CD3+ high | 100 | ||
| Hepatocellular carcinoma | 302 | CD8+ GrB low b | 45 | |
| Gao, 2007 [77] | CD8+ GrB high | 60 | ||
| Lung neoplasmsd | 1290 | CD8+ <20% of all cells | 30 | d |
| Ruffini, 2009 [67] | CD8+ >20% of all cells | 40 | ||
| Non-small-cell lung cancer | 219 | absent | 36 | e |
| Kilic, 2009 [66] | present | 76 | ||
| Endometrial carcinoma | 368 | CD8+ <4/0.3 mm2 | 60 | * e |
| de Jong, 2009 [64] | CD8+ >4/0.3 mm2 | 85 | ||
| Prostate carcinoma | 325 | rare/absent f | 30 | * e |
| Vesalainen, 1994 [90] | moderate | 55 | ||
| dense | 70 | |||
| Renal cell carcinoma | 221 | CD8+ scanty f | 85 | |
| Nakano, 2001 [93] | CD8+ aboundant | 60 | ||
| Ovary Carcinoma | 186 | CD3+ absent | 5 | |
| Zhang, 2003 [60] | CD3+ present | 38 | ||
| Breast Cancer | 1334 | CD8+ absent | 50 | * g |
| Mahmoud, 2011 [89] | CD8+ present | 65 | ||
*
Estimated on survival curves.
a
Only studies including >180 patients were considered.
b
High versus low TIL = above or below the median value.
c
Patients with lymph node metastasis were excluded.
d
Correlation between TIL infiltrate and survival observed for adenocarcinoma and squamous cell carcinoma.
e
10-year survival analysis.
f
Number of TIL estimated by immunohistochemistry.
g
20-year survival analysis.